First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations. Blasi M, Kuon J, Luders H, Misch D, et al. Eur J Cancer 2024;199:113556.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Blasi M, Kuon J, Luders H, Misch D, et al. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations. Eur J Cancer 2024;199:113556.
PMID: 38271745